Aurinia Pharmaceuticals Inc. (AUPH) Trading Down 3.2%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price fell 3.2% during mid-day trading on Wednesday . The company traded as low as $2.07 and last traded at $2.10, with a volume of 591,674 shares traded. The stock had previously closed at $2.17.
AUPH has been the topic of several recent analyst reports. Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, May 12th. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a “buy” rating and a $7.00 price objective on the stock. Leerink Swann reiterated an “outperform” rating and set a $7.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. Finally, FBR & Co reiterated an “outperform” rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $7.75.
The stock’s 50 day moving average price is $3.06 and its 200 day moving average price is $2.78. The stock’s market cap is $71.63 million.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.